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Abstract
Lung cancer is among the most common cancers worldwide and is the leading cause of cancer death in both men and
women. For patients with early stage (American Joint Committee on Cancer T1-2, N0) nonesmall-cell lung cancer, the
current standard of care is lobectomy with systematic lymph node evaluation. Unfortunately, patients with lung cancer
often have medical comorbities, which may preclude the option of surgical resection. In such cases, a number of
minimally invasive to noninvasive treatment options have gained popularity in the treatment of these high-risk patients.
These modalities provide signiﬁcant advantages, including patient convenience, treatment in an outpatient setting,
and acceptable toxicities, including reduced impact on lung function and a modest risk of postprocedure chest wall
pain. We provide a comprehensive review of the literature, including reported outcomes, complications, and limitations
of sublobar resection with or without intraoperative brachytherapy, radiofrequency ablation, microwave ablation,
percutaneous cryoablation, photodynamic therapy, and stereotactic body radiotherapy.
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Lung cancer is among the most common cancers worldwide and is
the leading cause of cancer death in both men and women.1 In the
United States alone, It is estimated that 226,150 cases of lung and
bronchus cancer were diagnosed in 2012, and the disease accounted
for 160,340 deaths.2 Nonesmall-cell lung cancer (NSCLC)
accounts for more than 85% of all lung cancer cases, with approxi-
mately 15% to 20% of patients presenting with early stage (T1-2,
N0) disease. Lobectomy with systematic lymph node evaluation is
considered the optimal treatment in patients with early stage
NSCLC. However, no randomized clinical data directly compare
surgery alone to radiation alone or ablative techniques in the man-
agement of patients whose disease is amenable to surgery.3 The
acceptance of lobectomy as the optimal therapy is based on historical
data, registry studies, and retrospective series, which consistently
demonstrate 5-year overall survival (OS) rates ranging from 60% to
80% and 40% to 60% for stage I and II NSCLC, respectively.4-6National Cancer Institute, Bethesda, MD
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options include best supportive care, limited resection (wedge
resection or segmentectomy), and external beam radiotherapy.
Studies demonstrate that limited resections generally result in 5-year
survival and recurrence rates of 59% and 50%, respectively.7
Deﬁnitive external beam radiotherapy delivered in standard frac-
tionation (45 to 66 Gy in 1.8 to 2 Gy per fraction) results in local
relapse in 55% to 70% of patients, with a reported median survival
of > 30 months and 5-year survival rates of up to 30%.8 These
consistently inferior results compared to lobectomy have led to new
therapeutic approaches in the management of such inoperable/high-
risk patients as well as those who decline operative intervention.
Here we provide a review of the primary treatment options
available for early stage NSCLC deemed to be high-risk or medically
inoperable. Such treatments include limited resection with and
without intraoperative brachytherapy, radiofrequency ablation
(RFA), microwave ablation (MWA), percutaneous cryoablation
(PCT), photodynamic therapy (PDT), and stereotactic body
radiotherapy (SBRT).
Review Methods
A review of the NSCLC treatment literature was conducted. A
comprehensive systematic literature search included the Cochrane
Collaboration Library electronic database, PubMed, RTOG.org,Clinical Lung Cancer November 2015 - 413
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414 -and ClinicalTrials.gov, using the following terms and keywords:
NSCLC, early stage, surgery, lobectomy, limited resection, wedge
resection, segmentectomy, EBRT, SBRT, RFA, MWA, cryoa-
blation, PCT, and brachytherapy, and a combination of these terms.
Studies were limited to those reported in the English language and
involving human subjects. Review articles and original data from the
last 30 years were reviewed independently.
Surgery
The standard treatment for operable early stage NSCLC is
lobectomy with systematic lymph node dissection.9 However, there
are currently no universally accepted deﬁnitions for medical oper-
ability.10,11 Factors including patient age, cardiopulmonary reserve,
presence and extent of medical comorbidities, and overall perfor-
mance status are included in the preoperative assessment.12 In
addition to the determination of operability, accurate nodal assess-
ment is considered critical as a result of the inﬂuence of nodal
staging on both the primary and adjuvant treatment options for
early stage disease. One study of 100 NSCLC patients with  1 cm
tumors demonstrated a 5% incidence of node involvement,
implying that even in small tumors, nodal assessment cannot be
ignored.13 Methods for analysis of nodal involvement include
computed tomography (CT) and/or positron emission tomography,
endobronchial ultrasound, transbronchial needle biopsy, and
mediastinoscopy.
Although lobectomy is considered the reference standard, pa-
tients with severe chronic obstructive pulmonary disease (COPD)
and poor lung function are at a substantially greater risk of post-
operative complications. The risk of complications for healthy in-
dividuals with normal lung function undergoing resection is
approximately 2% to 5%, while those with preexisting lung disease
have up to a 50% risk. Thus, preoperative studies including
complete pulmonary function testing (spirometry) to quantify
baseline pulmonary function and reserve is generally recom-
mended.11 If the forced expiratory volume in 1 second (FEV1) is
> 2 L or > 80% of its predicted value, resection can be attempted
with an acceptable risk of complications.10 Patients with an
FEV1 < 40% or carbon monoxide diffusing capacity (DLCO)
< 40% are at increased risk of perioperative morbidity and
mortality. Some investigators recommend nonoperative manage-
ment if the product of the percentage of predicted postoperative
FEV1 and DLCO combined is < 1650, if the percentage of pre-
dicted postoperative FEV1 is < 30%, or if the maximum oxygen
uptake is less than 10 mL/kg/min.9
In subjects with medical comorbidities, a more limited resection
may be offered to reduce the impact of lobectomy on lung function
and maintain the patient’s quality of life. One report suggested that
over 20% of patients with stage I or II NSCLC cannot undergo
lobectomy as a result of comorbid health factors.14 Limited
resections are generally offered to patients with poor baseline
cardiopulmonary function with tumors < 2 cm in diameter. In
patients with small, node-negative tumors excised to negative
margins, limited resection may result in local control (LC), OS, and
cause-speciﬁc survival (CSS) comparable to lobectomy.6,15-18
In 1995, the Lung Cancer Study Group published the ﬁrst
randomized, prospective study comparing limited resection to lo-
bectomy in the deﬁnitive management of T1N0 lung cancer.5,19Clinical Lung Cancer November 2015The study enrolled 247 patients with 125 randomized to lobec-
tomy and 122 to a limited resection (82 segmentectomies and
40 wedge resections). With a median follow-up of 60 months, LC
rates were 93.6% for the lobectomy group compared to 83% in
those treated with limited resection (P ¼ .008). Although the OS
was statistically comparable at 69.6% and 60.7% for lobectomy
versus limited resection (P ¼ .088), the local recurrence rate (0.020
to 0.060 per patient per year, P ¼ .008) for the patients undergoing
limited resection was tripled compared to lobectomy. The high rate
of local recurrence in the limited resection cohort resulted in critical
evaluation regarding the deﬁnitive role of sublobar resection.
A Surveillance, Epidemiology, and End Results (SEER) registry
study evaluated patients older than 65 years of age with stage IA
lung cancer (tumors  2 cm without clinically or radiographically
apparent lymph nodes) treated with either lobectomy or limited
resection. This analysis found no signiﬁcant difference in OS
between the treatment groups, but there was evidence of an
increased risk for lung cancer death after limited resection in
patients with tumors measuring 2 to 3 cm.20 Subsequently, Warren
and Faber17 evaluated the outcomes of stage I NSCLC patients with
poor cardiopulmonary reserve. The authors reported a higher risk of
locoregional recurrence in patients undergoing segmentectomy
versus those who had a lobectomy (22.7% and 4.9%, respectively),
although 5-year OS was equivalent.
Several other retrospective studies have demonstrated that
lobectomy and limited resection yield equivalent survival for
tumors  2 cm. For example, Okada and colleagues21 reported
5-year survival rates of 87.1% and 87.8%, respectively, for T1N0
tumors of < 2 cm and treated with extended segmentectomy (and
lymph node dissection) versus lobectomy. Koike and colleagues22
reported 5-year survival rates of 89.1% and 90.1%, respectively,
for limited resection versus lobectomy for peripheral T1N0 tumors.
Kodama and colleagues23 conducted a retrospective analysis of
patients with T1N0 lung cancer that again found no signiﬁcant
difference in 5-year survival in the lobectomy group (88%)
compared to the limited resection group (93%). Kates and col-
leagues24 queried the SEER database for stage IA tumors < 1 cm
and found no signiﬁcant difference in survival in 1402 patients who
underwent lobectomy compared to 688 patients treated with
limited resection.
Age at diagnosis is often an important determinant of outcomes
in NSCLC, in which patients present at an average age of 67 years
and approximately 45% of patients are 70 years or older at the time
of diagnosis.25 In fact, the postoperative mortality rate is 9.4% for
octogenarians and 1.7% for patients under the age of 60 years.15 A
SEER database study looking speciﬁcally at elderly patients with
stage I and II NSCLC was published by Mery and colleagues.26 The
study identiﬁed 9875 patients treated with lobectomy and 1403
treated with limited resection with evidence to suggest a decrease in
the utilization of lobectomy with an associated increase in the
number of limited resections as patient age increased (P < .0001).
Survival decreased with increasing age, with median survival times
of 71, 47, and 28 months for patients < 65, 65 to 74, and  75
years of age, respectively (P < .0001). In this analysis, lobectomy
conferred an OS beneﬁt over limited resection in both the < 65
(P ¼ .03) and 65 to 74 (P ¼ .0009) cohorts. However, for the
group  75 years of age, there was no difference in OS (P ¼ .47),
Guy C. Jones et alwith a loss of the statistical difference in long-term survival (> 25
months) in patients > 71 years of age in post hoc analysis.
Keenan and colleagues27 investigated whether segmental resec-
tion offered an advantage in preservation of lung function compared
to lobectomy. In a cohort of 201 patients with tumors less than 3
cm, of whom 147 underwent lobectomy and 54 underwent seg-
mentectomy, postoperative pulmonary function to include FEV1
and forced vital capacity were better preserved in the segmentec-
tomy group at 1 year of follow-up. LC rates at 30 months (92.5%
vs. 88.9%; P ¼ .22), 4-year actuarial survival (67% vs. 62%;
P ¼ .406), and 4-year CSS (82% vs. 74%; P ¼ .71) were com-
parable for lobectomy versus segmentectomy, respectively. In the
absence of a signiﬁcant difference in LC or OS, the authors
concluded that segmentectomy could be offered to patients with
small (< 3 cm), node-negative NSCLC with improved preservation
of pulmonary function. These results were supported by Okada and
colleagues,28 who reported on a nonrandomized study that
segmentectomy in early stage IA NSCLC produced outcomes
comparable to lobectomy in a group of 567 patients with 305 pa-
tients treated with lobectomy and 262 undergoing limited resection
(230 segmentectomy, 32 wedge resection). LC at 71 months
(93.1% vs. 95.1%; P ¼ .3524), 5-year OS (89.1% vs. 89.6%;
P ¼ .106), and disease-free survival (DFS) between the 2 groups
were not signiﬁcantly different in patients resected to a negative
margin ( 2 cm) with a negative nodal assessment.
In contrast, several studies have described signiﬁcant differences
in OS between lobectomy and limited resection. El-Sherif and
colleagues29 compared the outcomes of sublobar resection to lo-
bectomy in 784 patients with peripheral tumors less than 2 cm
conﬁned within anatomic segmental boundaries. Lobectomy was
performed in 577 patients and limited resection (consisting of either
segmentectomy or wedge resection) in the remaining 207 patients.
The median tumor size for the lobectomy and limited resection
groups were 2.8 versus 1.8 cm. With a median follow-up of 31
months, LC for the lobectomy group was 95.8% compared to
92.8% for the limited resection group. The 5-year OS for the
lobectomy group was 54% compared to 40% for the limited
resection group (P ¼ .0038); however, no signiﬁcant difference was
identiﬁed between the 2 groups in regard to DFS. The authors
suggested that the improvement in OS was due to other variables,
given the similar DFS and evidence to support increased use of
sublobar resection in patients with competing comorbidities and
increased risk of death. Sienel and colleagues30 evaluated outcomes
in high-risk T1N0 NSCLC patients treated with lobectomy
compared to segmentectomy. The local recurrence rate was 16% in
patients with segmentectomy compared to 5% for lobectomy.
The CSS was 68% for segmentectomy and 83% for lobectomy
(P ¼ .01). Similarly, Kraev and colleagues31 compared 215 patients
who underwent lobectomy to 74 patients treated with wedge
resection for stage I NSCLC. In the entire cohort, there was a trend
toward improved survival with lobectomy (5.8 vs. 4.1 years), while
in patient with  3 cm tumors, there was a statistically signiﬁcant
improvement in survival (P ¼ .029).
Further retrospective reports have described mixed nonsigniﬁcant
differences in survival between lobectomy and limited resection for
patients with poor cardiopulmonary function. Errett and col-
leagues16 reported a 6-year survival of 69% versus 75% in favor oflobectomy, while Pastorino and colleagues32 found the 5-year sur-
vival for limited resection in high-risk patients was actually slightly
better, at 55% compared to 49% in the lobectomy group. Similarly,
Read and colleagues33 reported a higher 5-year survival, 84% and
74%, in 244 patients with T1N0 tumors treated with limited
resection (n ¼ 113) versus lobectomy (n ¼ 131), respectively.
Martin-Ucar and colleagues34 reported on a case-matched anal-
ysis of segmentectomy versus lobectomy in high-risk (FEV1
< 40%) stage I NSCLC patients. Seventeen patients underwent
segmentectomy and 17 underwent lobectomy. The study found
that there was no signiﬁcant difference in survival, local recurrence,
or DFS between the 2 groups. There was an improvement in FEV1
(P ¼ .02) and quality of life after segmentectomy. A similar study of
T1N0 NSCLC patients treated with either lobectomy or limited
resection found that those treated with limited resection were older
and had more comorbidities than the lobectomy cohort; however,
the 5-year survival of the 2 groups (64% for lobectomy and 66.7%
for limited resection) was not statistically different.35
Landreneau and colleagues6 retrospectively evaluated 2 forms of
limited resectionewedge resection via video-assisted thoracic sur-
gery (VATS) or open wedge resection and compared these tech-
niques to lobectomy. Of 219 patients, 117 underwent lobectomy
and 102 underwent wedge resection (42 via open wedge resection
and 60 via VATS). The median tumor size by procedure was 2, 1.7,
and 1.7 cm for lobectomy, VATS wedge, and open wedge resection,
respectively. With a median follow-up of 26 months, the LC by
procedure was 91%, 84%, and 76% with postoperative complica-
tion rates of 31%, 16%, and 28%, respectively. One-year survival
for the lobectomy group was 91% compared to 94% for the
combined wedge resection group. Five-year survival was signiﬁ-
cantly better in the lobectomy group compared to the combined
wedge resection group (70% vs. 61.5%, P ¼ .02). A more recent
study compared open wedge versus VATS resection in regard to
outcomes and costs and demonstrated that VATS had several
advantages, including a reduction in expense, a decrease in adverse
events, and decreased time spent in the hospital.36
Schuchert and colleagues37 reviewed 428 patients undergoing
lobectomy or segmentectomy to study the effect of margin status on
outcome. Two hundred forty-six patients underwent lobectomy and
182 underwent segmentectomy. The average tumor size was 3.1
and 2.3 cm for the lobectomy and the segmentectomy group,
respectively. When analyzed collectively, the mean margin among
patients with recurrence was 12.8 versus 18.6 mm in patients
without recurrence. Margin/tumor diameter ratios exceeding 1 were
associated with a signiﬁcant reduction in recurrence rates compared
to ratios of less than 1 (6.2% vs. 25%, P ¼ .001). Although follow-
up varied between the 2 groups, outcomes were comparable. The
LC rate was 95.2% versus 92.3%, and the 4-year OS estimates were
80% versus 83% for lobectomy versus segmentectomy, respectively;
there was no signiﬁcant difference in DFS between the groups.
Table 1 provides a summary of the studies that have reported on
sublobar resection for lung cancer. These demonstrate that limited
resection may allow for improved preservation of pulmonary func-
tion and similar OS compared to lobectomy at the expense of
diminished LC. Importantly, limited resections also carry risks
inherent to thoracic surgery, including perioperative complications
such as rial ﬁbrillation, prolonged air leaks, infection, and death.36Clinical Lung Cancer November 2015 - 415
Table 1 Studies Including Sublobar Resection
Study
(Year)
No. Patients
(No. Tumors)
Disease
Stage
Tumor
Location Tumor Size Follow-Up LC Rate
1 Year
Survival
2 Year
Survival OS CSS Complications
Lung
Function
Criteria
Lung Cancer
Study Group
(1994, 1995)5
247 (lobectomy
125, limited
resection 122
[segmentectomy
85, wedge 40])
T1N0 Peripheral 3 cm Mean 60 mo,
minimum 36 mo
(53 mo minimum
for lobectomy,
54 mo for
limited resection)
Lobectomy
93.6%, limited
resection 83%
(P ¼ .008)
Lobectomy 95%
(Fernando 2005
[review])
Lobectomy 80%
(Fernando 2005
[review])
Lobectomy
69.6%, limited
resection
60.7%
(P ¼ .088)
NA NA Preoperative
FEV1 50%
Landreneau
(1997)6
219 (wedge 102,
lobectomy 117)
Stage I
NSCLC
Peripheral Median wedge
1.8 cm,
lobectomy 2 cm
Mean wedge 27
mo, lobectomy
26 mo
Wedge 81%,
lobectomy 91%
Wedge 94%,
lobectomy 91%
Wedge w72%,
lobectomy
w87%
5 years: wedge
61.5%,
lobectomy,
70% (P ¼ .02)
NA Respiratory failure,
empyema, wound
infection, air leak,
myocardial infarction,
arrhythmias, sepsis
COPD 66.5%,
14%; FEV1 65%,
88%; DLCO
62%, 81%
Keenan
(2004)27
201 (lobectomy
147,
segmentectomy
54)
Stage I; NSCLC;
lobectomy
126 IA, 21 IB;
segmentectomy
47 IA, 7 IB
NA Lobectomy NA;
segmentectomy
55.5% 2 cm,
44.4% 2-3 cm
Lobectomy
32.9  1.6 mo,
segmentectomy
27.4 
2.2 mo (NS)
Lobectomy
92.5%,
segmentectomy
88.9%
(P ¼ .22)
Lobectomy 78%,
segmentectomy
81.5%; active
surveillance:
lobectomy 95%,
segmentectomy
92%
NA 4 years: active
surveillance
lobectomy 67%,
segmentectomy
62% (P ¼ .406)
4 years:
lobectomy 82%,
segmentectomy
74% (P ¼ .71)
Operative mortality:
lobectomy 4.8%,
segmentectomy
5.6%
FEV1 55.3%
Okada
(2006)28
567
(sublobectomy
305 [230
segmentectomy,
32 wedge],
lobectomy 262)
Sublobectomy,
lobectomy IA
(266, 217),
IB (7, 10),
IIA (10, 12),
IIB (2, 2),
IIIA (14, 15),
IIIB (6, 6)
Peripheral 2 cm;
sublobectomy
mean 1.57,
range 5-2 cm;
lobectomy mean
1.62 cm, range
0.8-2 cm
Sublobectomy
median 72 mo,
range
29-155 mo;
lobectomy
median 71 mo,
range
22-158 mo
Sublobectomy
95.1%,
lobectomy
93.1% (NS)
Sublobectomy
98% (Fernando
2010 [review])
Sublobectomy
96% (Fernando
2010 [review])
5 years:
sublobectomy
89.6%
(NS between
types;
P ¼ .4335);
lobectomy
89.1% (NS)
DFS, ﬁgure 2,
NS (P ¼ .2778);
sublobectomy
(NS between
types;
P ¼ .8667);
DFS at 5 years,
sublobectomy
85.9%;
lobectomy
83.4%
Sublobectomy
6.6%,
lobectomy
7.3%
(P ¼ .7429)
FEV1 (wedge
(n ¼ 18),
segmentectomy
(n ¼ 168),
lobectomy
(n ¼ 168); preop
2.29  0.59,
2.32  0.64,
2.32  0.58;
postop:
2.21  0.84,
2.10  0.62,
1.93  0.58
El-Sherif
(2006)29,a
784
sublobectomy
(wedge 122,
segmentectomy
85), SLR 207,
lobectomy 577
Stage I NSCLC:
sublobectomy
161 IA, 46 IB;
lobectomy
288 IA, 289 IB
NA Sublobectomy
median 1.8 cm,
lobectomy
median 2.8 cm
Median 31 mo Locoregional:
sublobectomy
86%,
lobectomy
92%
NA NA 5 years:
sublobectomy
40%, lobectomy
54%
(P ¼ .0038)
DFS: NS Perioperative
mortality:
sublobectomy
1.4%, lobectomy
2.6%
NA
Sienel
(2007)30
199
(segmentectomy
49, lobectomy
150)
Stage IA
NSCLC
NA 2.03 
0.96 cm,
segmentectomy
1.8  0.75 cm,
lobectomy
2.8  1.04 cm
Median 54 mo Segmentectomy
84%,
lobectomy 95%
(P ¼ .005)
NA NA 5 years:
79%; CRS:
segmentectomy
67%, lobectomy
83% (P ¼ .01)
CRS: signiﬁcantly
different;
segmentectomy
67%, lobectomy
83% (P ¼ .01)
NA Median FEV1:
segmentectomy
45%, lobectomy
44%
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Table 1 Continued
Study
(Year)
No. Patients
(No. Tumors)
Disease
Stage
Tumor
Location Tumor Size Follow-Up LC Rate
1 Year
Survival
2 Year
Survival OS CSS Complications
Lung
Function
Criteria
Schuchert
(2007)37
428
(segmentectomy
182, lobectomy
246)
Segmentectomy
IA 109, IB 73;
lobectomy
IA 114, IB 132
NA Segmentectomy
2.3 (0.2-7.0) cm,
lobectomy 3.1
(0.5-11.2) cm
Segmentectomy
mean 18.1 mo,
lobectomy
28.5 mo
Segmentectomy
92.3%,
lobectomy
95.1%
(P > .05)
Segmentectomy
w98%, lobectomy
w96%
Segmentectomy
w88%,
lobectomy
w90%
4 years:
segmentectomy
w83%,
lobectomy
w80% (NS)
DFS: ﬁgure
1A; no
signiﬁcant
difference
Segmentectomy
32.4%; overall,
13.2% major;
lobectomy 33.7%;
overall, 13.8
major; AF 9.2%
FEV1:
segmentectomy
1.7 (70%),
lobectomy 1.81
(74%); DLCO:
segmentectomy
13.9 (66%),
lobectomy 15.1
(69%)
Wisnivesky
(2010)20
1165
(lobectomy
969, limited
resection 196)
Stage I NSCLC NA 2 cm:
lobectomy
1.59  0.37 cm,
limited resection
1.49  0.41 cm
59 mo NA NA NA HR 1.09 (NS) HR 1.39 (NS) NA NA
Zemylak
(2010)88
64 (SLR 25,
RFA 12,
PCT 27)
Stage I NSCLC NA Not deﬁned 33 mo SLR 88%,
RFA 67%,
PCT 89%
(P > .05)
NA NA 3 years OS:
SLR 87.1%,
RFA 87.5%,
PCT 77%
3 year CSS:
SLR 90.6%,
RFA 87.5%,
PCT 90.2%
Pneumothorax,
hemoptysis
Major criteria:
FEV1 50%
predicted,
DLCO 50%
predicted; minor
criteria: FEV1
51%-50%,
DLCO
51%-60%;
pulmonary
hypertension
Abbreviations: SLR ¼ sublobar resection; COPD ¼ chronic obstructive pulmonary disease; CRS ¼ cytoreductive surgery; CSS ¼ cause-speciﬁc survival; DFS ¼ disease-free survival; DLCO ¼ carbon monoxide diffusing capacity; FEV1 ¼ forced expiratory volume in 1 second;
HR ¼ hazard ratio; LC ¼ local control; NA ¼ not applicable; NS ¼ not statistically signiﬁcant; NSCLC ¼ nonesmall-cell lung cancer; OS ¼ overall survival; PCT ¼ percutaneous cryoablation; RFA ¼ radiofrequency ablation.
aAnalysis based on sublobectomy, not wedge/segmentectomy.
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418 -Thus, lobectomy remains the standard treatment of early stage lung
cancer, with limited resection reserved as an option for high-risk
patients.
Intraoperative Brachytherapy After
Limited Resection
Intraoperative brachytherapy has the potential to improve LC
after limited resection of early stage NSCLC.38-40 Such low-dose-
rate brachytherapy techniques permit delivery of radiation doses
to the high-risk surgical bed over a period of weeks to months with
the additional advantages of predictable, focal, and highly conformal
dose distribution with decreased adverse effects resulting from a
reduction in the irradiated normal tissue volume.41
An early report described 14 patients who received brachytherapy
after wedge resection of peripheral lung cancers.42 The patients had
an average FEV1 of 23% and tolerated the intervention well, with
no reported cases of radiation pneumonitis. Chen and colleagues43
evaluated administration of iodine-125 (I-125) mesh brachytherapy
in high-risk stage I NSCLC patients. Twenty-three patients un-
derwent VATS and intraoperative brachytherapy to a total dose of
100 to 120 Gy to the staple line and tumor bed plus a 1 cm margin.
Postoperative pulmonary function testing performed at 3 months
revealed no signiﬁcant changes in FEV1 from baseline.
Voynov and colleagues44 assessed the delivery of 100 to 120 Gy
via I-125 Vicryl mesh to the staple line plus a 2 cm margin in 110
patients with stage IA and IB NSCLC. The 5-year LC was 90%,
locoregional control was 61%, and OS was 18%, with most deaths
reported as not cancer related. Lee and colleagues45 evaluated 33
patients with early stage NSCLC (35 primary tumors) who were not
candidates for lobectomy or pneumonectomy treated with limited
resection and brachytherapy seed implantation along the resection
margin. The 5-year survival was 47% for all patients, while those
with T1N0 lesions had a 5-year survival of 67%; those with T2N0
lesions demonstrated a 5-year survival of 39%, with 2 local relapses
and 6 patients experiencing regional recurrence.
Santos and colleagues46 analyzed data for high-risk NSCLC pa-
tients with poor cardiopulmonary reserve treated with surgical
resection with or without permanent intraoperative I-125 brachy-
therapy prescribed to a dose of 100 to 120 Gy. Regional and distant
failure rates as well as OS were not signiﬁcantly improved with the
addition of brachytherapy; however, the rate of local recurrence was
decreased (2% vs. 18.6%, P ¼ .001). A similar ﬁnding was reported
by Fernando and colleagues,47 who evaluated 291 high-risk patients
with stage IA NSCLC, 60 of whom received brachytherapy in
conjunction with a sublobar resection. In these patients, the addi-
tion of brachytherapy associated with a decreased local recurrence
rate (17.2% vs. 3.3%, P ¼ .012).
Birdas and colleagues48 looked at 167 patients with high-risk
stage IB NSCLC, of whom 126 underwent lobectomy and
41 underwent sublobar resection with brachytherapy. The average
tumor size was not equivalent between the 2 groups, reported as 4.3
cm for the lobectomy group and 3.3 cm for those in the brachy-
therapy group (P ¼ .007). The local recurrence rates (4.8%) were
identical in both groups, and there was no signiﬁcant difference in
4-year DFS (43% and 42.8%). Pulmonary complications were
increased in those treated with sublobar resection when brachy-
therapy was added (24.4% vs. 16.6%).Clinical Lung Cancer November 2015Parashar and colleagues38 retrospectively reviewed 47 patients
who underwent wedge resection and intraoperative brachytherapy
versus SBRT alone for treatment of a single malignant lung nodule.
Twenty-two patients were treated with brachytherapy after resection
and 25 patients with SBRT alone. LC, distant metastasis rates,
survival, and toxicity were all comparable between the 2 cohorts,
with the caveat that there was a signiﬁcant difference in age between
the patients in each group (66.6 years in the brachytherapy group
and 75.9 years in the SBRT group, P ¼ .04).
Martinez-Monge and colleagues49 provided preliminary data
with brachytherapy alone in 7 patients who were deemed to have
medically inoperable early stage NSCLC. Brachytherapy was per-
formed via CT-guided placement of palladium-103 or I-125 sources
in tumors with an average volume of 11.5 cm3 resulted in no local
or regional failure with a median follow-up of 13 months. Two
patients died from stroke and liver failure, while one developed a
new primary lung tumor at 8 months in the contralateral lung.
The American College of Surgeons Oncology Group (ACO-
SOG) Z4032 study was a prospective comparison of sublobar
resection with or without brachytherapy for high-risk operable
patients (FEV1 < 50%) with NSCLC (< 3 cm). The study
enrolled 224 patients with 115 patients randomized to surgery and
109 patients to surgery combined with brachytherapy. An initial
presentation of the data at the American Society of Clinical
Oncology 2013 annual meeting suggested that local recurrence
and OS rates at 3 years were similar between arms. Fernando and
colleagues50 published the updated results at a median follow-up
of 4.38 years. Only 17 of 222 patients experienced local pro-
gression, and there was no signiﬁcant difference in the time
to local recurrence or in the type of local recurrence with the
addition of brachytherapy. Interestingly, there was no signiﬁcant
improvement in local recurrence rate or OS with the addition of
brachytherapy even among patients with potentially compromised
surgical margins. Intraoperative brachytherapy did not signiﬁ-
cantly worsen pulmonary function or dyspnea at 3 months and did
not result in an increased rate of adverse events51 compared to
surgery alone. To our knowledge, there have been no recent re-
ports regarding an overall trend in the use of intraoperative
brachytherapy; however, our general sense is that it has been
offered less throughout the United States in recent years. Because
the ACOSOG Z4099 sublobar resection with or without
brachytherapy to SBRT in high-risk operable patients was closed
as a result of poor accrual in 2013, it is unclear at this time what
role this treatment modality will play in the future.
Radiofrequency Ablation
RFA is a relatively new treatment option for patients with
medically inoperable disease with primary NSCLC or metastatic
lesions involving the pulmonary parenchyma. After initial success in
the treatment of hepatic malignancies,52 RFA was introduced in the
treatment of patients with medically inoperable lung tumors and in
those who refused surgery (Table 2).
The goal of RFA is to induce thermal injury to the tumor
through electromagnetic energy deposition.53 Alternating current
produced by a radiofrequency generator moves from an active
electrode inserted within the tumor to dispersive electrodes placed
on the patient. During RFA, a high-frequency electrical current
Table 2 Studies Including Radiofrequency Ablation
Study
(Year)
No. Patients
(No. Tumors)
Patients per
Disease
Stage
Tumor
Location Tumor Size Follow-Up LC Rate
1 Year
Survival
2 Year
Survival OS CSS Complications
Lee
(2004)57
30 (32) 10 stage IA/B, 1
stage IIB,
15 stage III/IV,
4 Mets
Central
18 (56%),
peripheral
14 (44%)
5.2  2.4 cm 12.5 (range
1-24) mo
38% with
complete
necrosis at
least for 9 mo
NA NA Mean survival:
<3 cm:
18.6  2.2 mo;
>3 cm:
11.3  1.8 mo
(P ¼ .09)
NA 10% major
complication
ARDS or severe
PT all central
tumor
Fernando
(2005)60
18 (21) 9 stage I,
2 stage II,
3 stage III,
4 stage IV
Peripheral Median 2.8
(range
1.2-4.5) cm
Median
14 mo
61.9% 83% 83% NA PFS: mean and
median intervals
16.8 and 18 mo;
stage I, mean
interval 17.6 mo
PT 38.9%,
pneumonia
11.1%, air leak
5.6%, PE 5.6%
Hiraki
(2006)61
128 (342) 25 primary,
317 Mets
Central
90 (26%),
peripheral
252 (74%)
1.7  1.2 cm Median 12 mo 73% (1-30 mo
after ﬁrst
ablation)
NA NA NA NA NA
Yan
(2006)62
55 26 stage I/II,
29 stage III/IV,
colorectal
pulmonary Mets
Central
10 (18%),
peripheral
45 (82%)
<5 cm 24 (range
6-40) mo
62% (at time
of 40 mo
follow-up)
Stage I/II 92%,
stage III/IV 79%
3 years:
stage I/II 69%,
stage III/IV 38%
33 mo median OS;
actuarial survival: 1
year 85%, 2 years
64%, 3 years 46%
PFS: 15 mo PT 29%, fever
11%, pleural
effusion 7.2%,
PCP 3.6%
Pennathur
(2007)64
19 11 stage IA,
8 stage IB
Peripheral Mean 2.6
(range
1.6-3.8) cm
29 mo 58% at
27 mo
95% 68% NA NA PT 63%,
air leak 5%
Simon
(2007)65
153 (189) 116 stage I
NSCLC,
73 stage IV
colorectal
NA Mean 2.7 cm
for LC; mean
6.1 cm for
palliation
Median
20.5 mo
1, 2, 3, 4,
5 years, 83%,
64%, 57%, 47%,
47% (<3 cm); 1,
2, 3, 4, 5 years,
45%, 25%, 25%,
25%, 25% (>3 cm)
Stage I 78%,
stage IV 70%
Stage I 57%,
stage IV 54%
5 7: stage I 27%,
stage IV 44%
NA PT 28.4%,
chest tube 9.8%
Ambrogi
(2007)65
50 30 stage I
NSCLC,
14 stage IV
1 cm from major
blood vessels
or airways
Mean 2.4 cm 31 mo 61% NA NA Stage I NSCLC 28.9
mo, all 25 mo
NA NA
Lencioni
(2008)66
106 (183) 33 stage I
NSCLC, 53
colorectal
Mets, 20
other Mets
1 cm from
trachea, main
bronchi,
Right/left pulm
artery
Mean 1.7 cm Up to 2 years 1 year: 88% NA NA NSCLC: 70% at
1 year, 48% at
2 years; stage IV
colorectal: 89%
at 1 year, 66% at
2 years; other: 92%
at 1 year, 64%
at 2 years
NSCLC: 92% at 1
year, 73% at 2
years; stage IV
colorectal: 91%
at 1 year, 68%
at 2 years; other:
93% at 1 year,
67% at 2 years
PT 20%
Lanuti
(2009)67
31 (34) 29 T1N0,
5 T2N0
Peripheral 2.0  1.0 cm 17 mo 68.5% at 17 mo 85% 78% 3 years: 47%
median OS 30 mo
DFS: 57% at 2
years, 39% at 3
years, median
25.5 mo
PT 13%,
pneumonia 16%,
pleural effusion
21%
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420 - Clinical Lung Cancer November 2015heats and coagulates tissue. The temperature within the tumor rises
to > 60C, resulting in instantaneous cell death via protein dena-
turation and coagulation necrosis.
Advantages of RFA compared to resection include treatment in
an outpatient setting and the ability to complete nonoperative probe
placement via CT guidance with the use of local anesthesia. Damage
to the surrounding normal tissues and lung parenchyma is limited as
a result of the presence of air, which provides an insulating effect
allowing for dissipation of the energy and protection of nearby
normal tissues; however, the procedure can result in complications
such as pneumothorax, hemoptysis, bronchopleural ﬁstula, rib
fracture, and tissue injury.54
Limitations of RFA include the inability to treat tumors in close
proximity to vascular structures and the size and location of the
tumor. Vessels larger than 3 mm in diameter reduce the amount of
energy delivered to the target as a result of the loss of heat through
convection within the circulatory system, the so-called heat sink
effect.55 Size is a limiting factor, with evidence to suggest a loss of
LC in over 50% of lesions greater than 3 cm in diameter. As the
target volume increases, the periphery may not reach an ablative
temperature, resulting in diminished response and impaired LC.56
Location is critical as a result of the risk of damage to adjacent
nonpulmonary structures, including the esophagus and trachea.
Finally, post-RFA recovery from thermally induced inﬂammation
may require several months and may result in difﬁculty in inter-
preting tumor response with CT imaging.
Recent studies have examined the results of RFA as deﬁnitive
therapy for early stage NSCLC. Lee and colleagues57 assessed the
technical feasibility, efﬁcacy, and complications of percutaneous
CT-guided transthoracic RFA in the treatment of inoperable
NSCLC and lung metastasis. Thirty patients with 32 lung tumors
were evaluated. The average tumor size was 5.2 cm (range, 2.8 to
7.6 cm) and patients had a median follow-up time of 12.5 months.
Each patient received a single ablation. The complete necrosis rate
(assessed by enhancement on CT imaging and read by an experi-
enced radiologist) in the study was reported at 38%. Tumors
smaller than 3.0 cm in diameter demonstrated higher complete
necrosis rates compared to tumors larger than 5.0 cm (100% vs.
8%) with a median survival of 18.6  2.2 months compared to
11.3  1.8 months, respectively (P ¼ .09). The authors reported a
10% rate of major complications, including 2 pneumothoraces
requiring tube thoracotomy and 1 patient with acute respiratory
distress syndrome.
Huang and colleagues58 performed a retrospective review of 329
patients with 436 lung tumors (237 primary and 92 metastatic lung
tumors) treated with RFA as a result of refusal of surgery or inability
to undergo surgical resection. RFA resulted in a median progression-
free interval of 21.6 months. Local progression occurred in 23.7%
of patients, with a signiﬁcant difference in the risk of progression in
tumors > 4 cm (P ¼ .01). OS at 1, 2, and 5 years was 68.2%,
35.3%, and 20.1%, respectively, with a low 30-day mortality of
0.6%. A second study evaluated 79 patients with 79 primary lung
tumors treated with RFA to include 35 patients with stage IA and 7
patients with stage IB NSCLC.59 The study included 19 patients
(24%) and 9 patients (11%) treated with adjuvant external beam
radiotherapy and concomitant brachytherapy, respectively. The
median OS was 23 months and the overall recurrence rate 43%
Guy C. Jones et al(34 of 79), with local failure as the dominant pattern, occurring in
38% (13 of 34). Increasing size of tumor and higher disease stage
were signiﬁcant for increased likelihood of disease recurrence.
Fernando and colleagues60 studied 21 tumors in 18 patients with
a median tumor size of 2.8 cm. Each patient received 1 ablation,
with CT and positron emission tomography utilized to evaluate
response and recurrence. At a median follow-up of 14 months, the
LC rate was 61.9%. One- and 2-year survival rates were 83% and
83%, with median progression-free survival (PFS) of 16.8 months.
Hiraki and colleagues61 reported on 342 tumors in 128 patients
with an average tumor size of 1.7 cm. For the 342 tumors, the
authors performed 225 ablative sessions to include 49 repeat
sessions for the treatment of local progression. Chemotherapy
was administered for 193 tumors. With a median follow-up time of
12 months, the nonactuarial LC rate was 73%. The 2-year LC rate
was 66% for tumors that were ablated once and 78% for those
ablated more than once. They found that tumor size > 2 cm and
the use of an internally cooled electrode were independent risk
factors for local progression.
Yan and colleagues62 reported on 55 tumors (26 patients with
stage I/II NSCLC) in 55 patients with an average tumor size of less
than 5 cm. With a median follow-up of 24 months, the overall LC
rate was 62%. The median OS time for the entire cohort was 33
months with a median PFS of 15 months. The subgroup with stage
I/II NSCLC demonstrated a 1-year survival of 92% and a 3-year
survival of 69%. Multivariate analysis demonstrated that lung
metastasis > 3 cm was independently associated with a reduced OS
(P ¼ .003). Ambrogi and colleagues63 studied 50 tumors in 50
patients with a mean tumor size of  5.0 cm. The average follow-up
time was 31 months, and the LC was nearly identical, at 61%.
Another similar experience was reported by Pennathur et al64 with a
documented local progression rate of 42% and 2-year OS of 49%
after treatment of 19 patients with stage I NSCLC.
Simon and colleagues65 evaluated 153 consecutive patients with
189 primary NSCLCs (n ¼ 116) or stage IV colorectal pulmonary
metastasis (n ¼ 73) to determine the long-term survival, local tumor
progression, and complication rates after CT-guided RFA. Mean
tumor size was 2.7 cm for tumors treated with curative intent and
6.1 cm for tumors treated with palliative intent. At a median follow-
up of 20.5 months, the 1-, 2-, 3-, 4-, and 5-year LC rates for
tumors < 3 cm in diameter were 83%, 64%, 57%, 47%, and 47%,
respectively. For tumors > 3 cm, the 1-, 2-, 3-, 4-, and 5-year LC
rates were 45%, 25%, 25%, 25%, and 25%, respectively. Stage I
patients had 1-, 2-, and 5-year survival rates of 78%, 57%, and
27%, whereas the rates for colorectal pulmonary metastasis were
70%, 54%, and 44%, respectively. These results underscore the
highly selective nature of patients chosen for this therapy in that
outcomes varied widely based on tumor size and disease stage.
Lencioni and colleagues66 described 183 tumors in 106 patients
with a mean tumor size of 1.7 cm. Patients were divided into 3
groups: NSCLC (n ¼ 33), colorectal metastasis (n ¼ 53), and other
metastasis (n ¼ 20). Each patient received 1 RFA treatment. The
reported 1-year LC rate was 88%, and 1- and 2-year OS rates for
patients with NSCLC were 70% and 48%, respectively, and 89%
and 66% for patients with metastases from a colorectal primary
lesion. Patients with stage I NSCLC had a 2-year OS and CSS of
75% and 92%, respectively. Lanuti et al67 reviewed 34 tumors in 31patients with an average tumor size of 2 cm. At a mean follow-up
time of 17 months, the LC rate was reported as 68.5%. The
4-year survival rate was 47% with a DFS at 2 and 3 years of 57%
and 39%, respectively. As previously noted, the size of the target
lesion is an important consideration in patient selection for RFA.68
Simon and colleagues65 demonstrated a 3-year LC of 57% in
tumors < 3 cm in diameter compared to 25% in tumors > 3 cm in
diameter. Bilal et al69 performed a literature search to compare the
results of RFA and SBRT in the treatment of early stage medically
inoperable NSCLC. On the basis of a review of 16 representative
publications, the authors concluded that SBRT resulted in
improved 5-year OS and decreased local progression compared to
RFA, 48% versus 20.1%-27%, and 3.5%-14.5% versus 23.7%-
43%, respectively.
In summary, RFA has generally been associated with inferior LC
compared to surgery and SBRT, where 3-year LC rates approximate
80% to 95%. Further studies with larger sample sizes and adequate
follow-up are necessary to better delineate the role of this emerging
modality. Trials such as ACOSOG Z4033, designed to evaluate
RFA in the treatment of high-risk patients with early stage NSCLC,
will help determine which patients this procedure will help most.
This trial has completed accrual, but survival and recurrence data
have not yet matured.
Microwave Ablation
MWA is a second heat-based ablation technique, similar to RFA
in application and technique. MWA can be delivered either
percutaneously under CT guidance or via open surgical or laparo-
scopic techniques. In contrast to RFA, thermocoagulation of the
target lesion is a result of an electromagnetic wave that produces
excitation and oscillation of water molecules within the tissue
surrounding the probe (antenna). Given the properties of the
electromagnetic wave, MWA does not require a grounding pad, as
intratumoral temperatures can be measured through placement of a
separate thermocouple located adjacent to the microwave
antenna.70,71
Theoretical advantages of MWA over RFA include enhanced
thermocoagulation of tumor cells as a result of improved energy
deposition in aerated lung and increased heating near blood vessels.
MWA allows for increased intratumoral temperatures with genera-
tion of a larger ablation zone (up to 2 cm from the probe tip) in a
shorter period of time compared to RFA.72 Additionally, MWA
may permit improved treatment of both peripheral and central
lesions as a result of a reduction in pain with the use of microwaves
and minimal heat sink effect associated with vasculature. Similar to
RFA, MWA is associated with risk of pneumothorax, post-
procedural pain, hemoptysis, and, rarely, pulmonary toxicity.
Relative contraindications for both RFA and MWA include possible
interference with the electromagnetic current of implantable cardiac
devices and unpredictable pattern of ablation as a result of the
presence of surgical clips.70,73,74
Much like RFA, MWA was ﬁrst implemented as a treatment
strategy for hepatic tumors,75 with gradual expansion into the
treatment of pulmonary lesions. Feng et al76 reviewed the results of
MWA in the treatment of 28 lesions in 20 peripheral lung cancer
patients (8 primary and 12 metastatic disease). With an overall
response rate of 57.1%, a more than 50% ablation was noted inClinical Lung Cancer November 2015 - 421
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422 -13 (46.4%), with complete response in 3 (10.7%). No signiﬁcant
adverse effects or complications were observed. Wolf and col-
leagues77 retrospectively reviewed the results of percutaneous
CT-guided MWA in 82 lung lesions in 50 patients. With a mean
follow-up of 10 months, the 1-year LC was 67%, with 26% of the
patients demonstrating residual disease at the ablation site. Kaplan-
Meier analysis demonstrated an actuarial survival at 1, 2, and 3 years
of 83%, 73%, and 61%, respectively. Interestingly, cancer-speciﬁc
mortality was not signiﬁcantly affected by index size of larger
than 3 cm or the presence of residual disease.
Limited outcome data are available to support the use of MWA
in the treatment of early stage NSCLC. As with RFA, MWA can be
considered in the treatment of recurrent disease or in combination
with other techniques to provide palliation of progressive pulmo-
nary lesions. Future studies will, we hope, clarify the role of MWA
in the treatment of high-risk NSCLC.
Percutaneous Cryoablation
PCT, another thermal-based ablative technique, utilizes cold
temperatures as opposed to heat. The therapeutic role of cryoa-
blation is based on the Joules-Thompson effect with the utilization
of a gas, typically argon, which rapidly decreases to subzero tem-
peratures (as low as 150C) upon transition from a liquid to
gaseous state. Experiments have demonstrated that a 2 to 3 mm
diameter probe can result in a freeze area 2 to 3 cm in diameter and
4 cm in length. The probe temperature is measured potentio-
metrically with a needle placed approximately 2 mm from the tip.
The freeze cycle is alternated with a thaw cycle, during which
helium gas is administered to raise the temperature to approximately
40C. The diameter and number of probes and the number of
freeze/thaw cycles is dependent on the size, location, and clinical
scenario.
The alternating freeze/thaw cycles of PCT result in cell death
through both direct and indirect mechanisms. Rapid freezing results
in formation of both intracellular and extracellular ice crystals,
which disrupt the cell membrane and internal cellular processes.
Indirect actions include vasoconstriction and occlusion of blood
vessels resulting from osmotic changes and local tissue edema
resulting in hypoxic tissue injury and coagulative necrosis.56,78-81
Additionally, cryoablation generates immunologic interactions and
promotion of inﬂammatory cytokines,82 which may also exert a
tumoricidal effect.
Similar to RFA, PCT is recommended for lesions less than 3 cm
as a result of difﬁculty with probe geometry in the treatment of large
or irregular lesions, resulting in increased risk of recurrence.
Successful ablation requires generation of a cryozone approximately
1 cm beyond the radiographically imaged tumor and a minimum
isotherm of 20C to result in cell death. PCT also suffers from the
heat/cold sink effect, as with RFA.
In contrast to RFA, PCT is recommended for treatment of
central tumors due to the relative resistance of collagenous archi-
tecture allowing for minimization of damage to adjacent organs.83
Because of the delayed effects of cryotherapy, with development
of nonhemorrhagic necrosis 8 to 14 days after treatment, the
technique is not recommended for immediate debulking or man-
agement of an obstructing lesion.84 Cryotherapy may result in less
pain in the treatment of tumors along the pleura and chest wall.56Clinical Lung Cancer November 2015The main complications of PCT include pneumothorax, hemor-
rhage, ﬁstula formation, and bronchospasm, similar to RFA and
MWA.78,85
Cryoablation initially gained acceptance in the intraoperative
management of prostate and hepatic malignancies. Bronchoscopi-
cally directed cryotherapy has been utilized since the 1980s to treat
superﬁcial endobronchial lesions in both the deﬁnitive and palliative
settings.56 Maiwand and Asimakopoulos86 treated 521 patients with
advanced obstructive tracheobronchial malignant tumors with
cryotherapy and demonstrated that the treatment provided a palli-
ative beneﬁt with reduction in hemoptysis, cough, dyspnea, and
chest pain in 76.4%, 69%, 59.25%, and 42.6% of patients,
respectively. Improvement in 1 or more symptoms was noted in
86% of patients, with a median survival of 8.2 months. Other in-
vestigators have demonstrated the safety and efﬁcacy of cryotherapy
delivered via direct thoracoscopic guidance in the treatment of
symptomatic inoperable lung cancer.
Wang and colleagues78 reported their experience on the use of
PCT in the treatment of 234 pulmonary masses in 187 patients.
The review included a heterogeneous patient population, with 89%
diagnosed with advanced pulmonary malignancies in which prior
treatment, including surgery, chemotherapy, and radiotherapy, had
failed. Stage I and II primary lung tumors represented only 17 and
20 lesions, respectively. The authors concluded that CT-guided
PCT may allow for improved therapeutic beneﬁt compared to
other ablative modalities, with a low procedural morbidity and
accurate treatment localization. Kawamura and colleagues85 per-
formed PCT in the treatment of 35 metastatic lung tumors in 20
patients over 22 sessions. With a median follow-up of 21 months,
20% of tumors recurred, with complications including pneumo-
thorax in 11 sessions, hemoptysis in 8, and 1 case of phrenic nerve
palsy. One-year survival was estimated at 89.4%.
Choe and colleagues87 investigated the efﬁcacy of PCT and RFA
in the management of 76 lesions in 65 patients with inoperable lung
malignancies. Sixty-seven total lesions were treated with RFA, while
9 tumors were managed with PCT. Twenty patients in the RFA
group and 3 patients in the PCT cohort were diagnosed with stage I
NSCLC. With a median follow-up of 20.8 months, complete
ablation was achieved in 76.2% of patients treated with RFA and
85.7% in the PCT group when the lesion was less than 3 cm in
diameter. Larger lesions resulted in an inferior complete response
rate of 43.3% and 66.7% in the RFA and PCT patients,
respectively.
Zemlyak et al88 compared the results of RFA, sublobar resection
and PCT in 64 patients with biopsy-positive stage I NSCLC
deemed unﬁt for lobectomy. With a median follow-up of 33
months, 3-year CSS for sublobar resection, RFA, and PCT was
90.6%, 87.5%, and 87.5%, respectively. OS was 60.8%, 87.1%,
and 77%, respectively. The authors noted a trend toward increased
local (33%) and regional/distant recurrence (25%) in the RFA
cohort. Yamauchi and colleagues89 retrospectively reviewed the
results of 34 tumors in 22 patients with histologically proven stage
I lung cancer. With a median follow-up of 23 months (range, 12 to
68 months), local tumor progression occurred in only 1 tumor
(3%). The mean maximal tumor diameter was 1.4 cm. The median
OS was 68 months, with 2- and 3-year DFS of 78% and 67%,
respectively.
Guy C. Jones et alThe limited number of early stage NSCLC patients and the
predominantly retrospective nature of the PCT literature does not
permit appropriate comparison of RFA or SBRT. The report from
Zemlyak et al88 included only 9 patients treated with PCT, of
which only 3 lesions were stage I NSCLC. Although the toxicity
proﬁle appears favorable and PCT may allow for improvement in
the therapeutic ratio compared to RFA and MWA, generalization of
this treatment modality in the deﬁnitive management of early stage
NSCLC requires prospective evaluation with larger patient numbers
and longer follow-up.
Photodynamic Therapy
The utilization of PDT in the treatment of thoracic malignancies
has increased over the last several years.90 PDT involves the
systemic delivery of a photosensitizing agent, typically porphyrin
based, followed by direct excitation of the compound by a wave-
length of light that correlates to the absorption band of the infused
drug. The resulting photodynamic reaction results in the produc-
tion of singlet oxygen and local reactive cytotoxic agents. The
mechanism of cell death is multifaceted and believed to be due to
direct cell killing via both apoptosis and cell necrosis. Indirect
damage also occurs as a result of injury to the tumor vasculature
and a local inﬂammatory response with associated antitumor
immunogenic factors.90-93 Reported complications include hem-
orrhage, respiratory compromise, and skin burns related to systemic
administration of the agent and exposure to UV light.84
Simone and colleagues90 at the University of Pennsylvania pub-
lished an exhaustive review of the role of PDT in the treatment of
NSCLC. As described, the role of PDT in early stage NSCLC is
generally limited to small ( 1 cm) endobronchial lesions without
extracartilaginous invasion or lymph node involvement. The ability
for light to penetrate the target tissue and activate the photo-
sensitizing agent is a limiting factor in the role of PDT, with therapy
most effective in the treatment of minimally invasive lesions.94,95
Furuse et al96 published the results of a phase 2 study with
porﬁmer sodium (Photofrin II) in the treatment of 59 early stage,
centrally located squamous cell carcinomas in 49 patients. Overall,
85% of the lesions demonstrated a complete response, with a me-
dian duration of response of 14 months. The complete response rate
was 100% in smaller tumors < 5 mm compared to 38% in tumors
> 20 mm. Kato et al97 treated 264 central early stage NSCLC in
204 patients, of which 70% were stage 0% and 30% were stage I.
The maximum tumor dimension was < 20 mm in 87% of patients,
with a reported complete response rate of 95% in tumors with a
length < 5 mm, 94% in those 5 to 9 mm, and a decrease to only
44% in lesions > 20 mm. Several series report complete response
rates with PDT ranging from 62% to 100%, with the longitudinal
length of the tumor being an important determinant in response.94
Okunaka et al98 evaluated the role of PDT as a novel therapy for
patients with peripheral lung tumors < 1 cm in size deemed unﬁt
for surgery or radiotherapy. Patients received a photosensitizer
followed by CT-guided percutaneous insertion of needles with
internal catheters to allow for light administration. Nine patients
were treated, with 7 experiencing partial remission and 2 experi-
encing pneumothorax.
PDT is considered a safe and effective method of treatment for
noninvasive (dysplasia and carcinoma-in-situ) and early stage centralNSCLC and in patients requiring focal palliative therapy.94
Extensive endobronchial and aerodigestive lesions may require a
debulking procedure before the application of PDT as a result of
limited light penetration. Insufﬁcient data exist to support a role in
the management of peripheral NSCLC without an endobronchial or
central component.
Stereotactic Body Radiotherapy
In patients with early stage NSCLC unable to tolerate surgical
resection, radiotherapy has historically been considered the standard
alternative treatment. Deﬁnitive external beam radiotherapy, deliv-
ered in standard once-daily fractions (1.8 to 2 Gy per fraction),
resulted in long-term survival rates of 15% to 30%, with local
failure rates exceeding 50%.8,99,100 Sibley99 evaluated the results of
10 studies assessing the treatment of medically inoperable NSCLC
patients with radiotherapy. With a median dose of 60 to 66 Gy,
25% of patients died of intercurrent disease, 30% with distant
metastatic disease and 30% with local failure alone, illustrating the
lack of primary tumor control with conventional fractionation.
The published results of primary radiotherapy are inferior to
surgical resection for several key reasons. First, the disease of the
majority of patients treated with primary radiation is inoperable as a
result of signiﬁcant life-limiting medical comorbidities. Thus, the
surgical and radiation groups essentially consist of 2 very different
patient populations with a signiﬁcant bias in regard to long-term
outcomes and OS. Second, surgical patients typically undergo
formal pathologic staging and assessment of regional lymph nodes
allowing for consideration of adjuvant therapy to include post-
operative radiation and/or chemotherapy as indicated. In contrast,
patients treated with deﬁnitive radiation may never undergo surgical
lymph node sampling with treatment options based exclusively on
clinical and radiographic staging. Finally, the historical doses
delivered with conventional radiotherapy may have been biologically
inadequate for long-term LC.
Mehta et al101 described the radiobiologic rationale for dose per
fraction escalation based on evidence that doses in excess of 85 Gy
are required to achieve 50% long-term LC when utilizing standard
fractionation (2 Gy per fraction). Thus, the total dose to the tumor
must be increased from the standard range of 60 to 66 Gy in order
to deliver an adequate biologic effect to improve the LC of these
tumors. With conventional fractionation, a protracted radiation
schedule requiring periods of up to 10 weeks may be required to
deliver such a dose. However, the total duration of radiotherapy is of
pivotal importance in the treatment of NSCLC, with modeling to
suggest a 1.6% per day loss in survival with prolongation of the
treatment beyond 6 weeks as a result of accelerated tumor repo-
pulation.101-103
Stereotactic radiosurgery was ﬁrst developed in the 1950s for the
treatment of small intracranial lesions or the ablation of functional
intracranial regions104 with the intent of delivering a high dose of
radiation in a single session with submillimeter-level precision
through the utilization of stereotactic guidance. SBRT represents an
extension of these principles to sites outside of the central nervous
system. In 1994, Lax et al105 provided the ﬁrst description of a
stereotactic frame developed at Karolinska University Hospital and
discussed the methodology for delivery of stereotactic radiotherapy
to extracranial tumors. Subsequently, Blomgren et al106 were theClinical Lung Cancer November 2015 - 423
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in the treatment of 42 tumors (liver and lung) in 32 patients with a
reported LC of 80% during a follow-up period ranging from 1.5 to
38 months.
SBRT, also known as stereotactic ablative body radiotherapy
(SABR), is characterized by the use of a rigid and reproducible
immobilization device intended to minimize and regularize respi-
ratory and patient motion with collection of precise measurements
to account for tumor motion during both treatment planning and
delivery of each fraction. The use of highly conformal dose distri-
butions with rapid dose fall off and daily image guidance allow for a
reduction in the high-dose treatment volume, allowing for decreased
irradiation of surrounding normal tissues with an associated
reduction in toxicity.107 Treatment is typically delivered in 3 to 5
fractions over a 1- to 2-week period, ranging on average from 10 to
20 Gy per fraction (although single-fraction and more protracted
regimens are also in use). With SBRT, the radiobiologic principle of
tumor repopulation is of diminished importance as a result of
shorter overall treatment times, often less than 2 weeks,108 and the
ability to deliver an increased biologic effective dose (BED)
compared to traditional fractionation.109 The resulting BED of
SBRT is typically in excess of 100 Gy, in contrast to a BED of 79.2
Gy with standard fractionation (66 Gy in 2 Gy per fraction),
assuming an alpha/beta ratio of 10 for acutely responding tissue
(tumor). Fowler and colleagues110,111 at the University of
Wisconsin provided the ﬁrst analysis of the radiobiologic implica-
tions of SBRT and the role of linear quadratic modeling to describe
the effect of doses up to 23 Gy per fraction on both the tumor and
surrounding normal tissues.
McGarry et al and Timmerman et al112-114 demonstrated the
safety of SBRT in the treatment of early stage NSCLC in a phase 1
dose-escalation trial conducted at the University of Indiana. The
investigators utilized an extracranial frame with incorporation of a
ﬁducial stereotactic coordinate system and an abdominal compres-
sion device designed to minimize tumor motion through a reduc-
tion in respiratory excursion. Thirty-nine medically inoperable
patients with clinical stage IA or IB (T1 or T2,  7 cm) NSCLC
received SBRT with peripheral tumor doses initiated at a dose of
24 Gy (8 Gy per fraction  3 fractions) with escalation up to 60 Gy
(20 Gy per fraction  3 fractions) in the T1 cohort without
exceeding the maximum tolerated dose. Patients in the T2 cohort,
with tumors larger than 5 cm, experienced excessive toxicity at the
72 Gy dose (24 Gy per fraction  3 fractions) with the maximum
tolerated dose deﬁned at 66 Gy (22 Gy per fraction  3 fractions).
A phase 2 trial114 followed this experience to further assess
toxicity and LC in inoperable patients with early stage NSCLC.
Seventy patients were treated with doses ranging from 60 to 66 Gy
in 3 fractions as per the results of the phase 1 study. With a median
follow-up of 17.5 months, the reported LC at 2 years was 95% with
a 2-year OS of 54.7% and median OS of 32.6 months. Grade 3 to 5
toxicity was documented in 14 patients with a 2-year freedom from
severe toxicity in 83% with peripheral lesions compared to 54% in
patients with perihilar/central tumors. Bradley et al115 reviewed the
results of 91 patients enrolled onto a prospective database, with 83
patients referred for SBRT as a result of underlying comorbidities
and the remaining 8 patients refusing surgery. Eighty-three tumors
were peripheral and 8 were central (deﬁned as  2 cm from theClinical Lung Cancer November 2015bronchus or esophagus or located adjacent to the brachial plexus).
Peripheral tumors received 54 Gy (18 Gy per fraction  3 frac-
tions), while central tumors received a reduced dose of 45 Gy (9 Gy
per fraction  5 fractions) based on the toxicity data from Tim-
merman et al.112,114 The median tumor diameter was 2 cm with no
tumor > 5 cm. Fifty-eight patients with T1N0, 22 patients with
T2N0, 2 patients with T3N0 (chest wall), and 6 patients with
T1N0M1 disease were included. With a median follow-up of 18
months, the 2-year LC was 86% with distant metastasis or second
lung cancer as the predominant pattern of failure.
In 2010, Timmerman and colleagues116 reported the results of
the Radiation Therapy Oncology Group (RTOG) 0236, a phase
2 trial with inclusion of 55 medically inoperable patients with pe-
ripheral tumors < 5 cm (T1-2, N0) treated with SBRT. With a
median follow-up time of 34.4 months, the 3-year LC, DFS, and
OS were 97.6%, 48.3%, and 55.8%, respectively. The rate of
disseminated recurrence at 3 years was 22.1% (11 of 55), with only
2 patients experiencing regional failure. Treatment-related
morbidity was relatively low, with grade 3 events occurring in
12.7% and grade 4 in 3.6% of patients. There were no reported
SBRT-related patient deaths, possibly as a result of ineligibility of
patients with central tumors.
At the American Society of Radiation Oncology’s (ASTRO) 56th
annual meeting, Timmerman et al presented updated 5-year data
from the RTOG 0236 trial. The updated results showed only
4 primary tumor failures among 55 patients, resulting in a 5-year
primary failure rate of 7%. The rate of local recurrence was 20%,
owing primarily to intralobar recurrence. Additionally, 5-year
locoregional and distant recurrence rates were 38% and 31%
respectively. Updates on toxicity revealed 2 additional episodes of
grade 3 or higher, but no grade 5, toxicities.117 This update is
signiﬁcant because it shows that local recurrence rates with SBRT
appear to be similar to lobectomy series at 5 years, with minimal
increased severe toxicity after 3 years. The RTOG 0236 trial served
as the basis for RTOG 0813, a phase 1/2 protocol designed to
determine a safe and effective dose for central tumors. The study
was closed to accrual in 2013, and results have not yet been
published.
Since the ﬁrst experience of Timmerman and colleagues, a
number of platforms capable of SBRT have come into popular use,
including standard linear accelerator-based options, CyberKnife,
Tomotherapy, Viewray, and proton-based options. Additionally,
various immobilization devices, respiratory-tracking, and tumor
motion-gating options have been developed. Each has advantages
and disadvantages, and they vary considerably in the costs of
installation and maintenance, required treatment time, beam angle
capabilities, and beam modiﬁers. As the technology has developed,
an expanding number of institutional reports of SBRT for early
stage NSCLC are now available and are summarized in Table 3.
Le et al118 completed a phase 1 dose-escalation study designed to
investigate the optimal single-fraction SBRT dose in the treatment
of inoperable lung tumors. Thirty-two patients (21 T1-T2N0
NSCLC and 11 metastatic tumors) received SBRT with tumor
doses initiated at 15 Gy with escalation to a dose of 30 Gy. The
1-year OS was 85% with a 1-year freedom from local progression
of 91% with doses > 20 Gy compared to 54% in patients
who received less than 20 Gy (P ¼ .03). The overall rate of
Table 3 Studies Including Stereotactic Body Radiotherapy
Author
(Year)
No.
Patients
Patients
per
Disease
Stage
Tumor
Location
Tumor
Size Dose BEDiso Follow-Up
Local
Control
Rate
1 Year
Survival
2 Year
Survival OS CSS
Complications
or Toxicities
Lung
Function
Criteria
McGarry
(2005)113
47 19 stage IA,
28 stage IB
No location
criteria, all
patients
accepted
7 cm T1 stratum
24-60 Gy;
T2 stratum
24-72 Gy to
80% isodose
T1: 43.2-180
Gy; T2: 43.2-
244.8 Gy
T1: 27.4 mo,
T2: 19.1 mo
78% (9/10
occurred at
doses 16 Gy
per fraction)
NA NA NA NA Grade 3 or more
in 72 Gy cohort
Inoperable: 14
patients
oxygen
dependent
Le (2006)118 32 21 NSCLC,
11 metastatic
No location
criteria, all
patients
accepted
2.0-6.2 cm
tumor
diameter
15-30 Gy, <20
Gy (n ¼ 10),
25 Gy (n ¼ 20),
30 Gy (n ¼ 2)
37.5-120 Gy Not deﬁned 91% (>20 Gy
cohort), 54%
(<20 Gy
cohort)
89% NA NA NS Increased pulmonary
toxicity >25 Gy with
prior RT and volumes
>50 cm3
NA
Hof (2007)109 42 17 stage IA,
21 stage IB,
4-2 stage B
Peripheral Stage IA
<3 cm,
stage IB
>3 cm
15-24 Gy to
80% isodose
in single
fraction
24-81.6 Gy 15 mo 1 year 89.5%,
2 years 67.9%,
3 years 67.9%
74.5% 65.4% 3 years
37.4%
1 year 70.2%,
2 years 49.1%,
3 years 49.1%
Only mild reactions;
no grade 3 or 4
toxicities
FEV1 at least
0.8 L
Koto
(2007)119
31 19 T1,
12 T2
30 peripheral,
1 central
Median
2.5 cm
20 patients:
45 Gy/3/1
wk; 11 patients;:
60 Gy/8/2 wk
45 Gy group:
113 Gy;
60 Gy group:
105 Gy
32 mo 3 years:
stage IA
77.9%,
stage 40%
NA NA 3 years
71.7%
3 years 83.5% 24 patients grade 1
pneumonitis;
3 patients grade 2
acute pneumonitis; 1
patient grade 3 acute
pneumonitis
NA (not
surgical
candidates,
refused
surgery)
Onishi
(2007)120
257 164 stage IA,
93 stage IB
No location
criteria, all
patients
accepted
Median 2.8
(range
0.7-5.8) cm
18-75 Gy in
1-22 fractions
111 Gy
(median), 215
patients: 100
Gy median (117
Gy median), 42
patients: <100
Gy (79.6 Gy
median)
38 mo 86%: stage IA
87.8%,
stage IB
82.8%
(P ¼ .21);
BED 100
Gy: 91.6%;
BED <100
Gy: 57.1%
(P <.001)
NA NA 3 years
56.8%,
5 years
47.2%,
(5 years BED
>100 Gy:
53.9%,
BED <100
Gy: 19.7%)
(P <.05)
3 years 76.9%,
5 years 73.2%
1 patient chronic
segmental bronchitis
and wall thickening
(atelectasis);
2 patients grade 3
esophagitis;
3 patients grade
3 or 4 dermatitis; 4
patients rib fracture
adjacent to tumor
ECOG: 0-109,
1-103, 2-39,
3-6
Lagerwaard
(2008)121
206 129 T1,
90 T2
63% UL,
31% LL,
6% ML,
peripheral
689
6 cm 93-20 Gy/3,
99-12 Gy/5,
27-7.5 Gy/8
3-180 Gy,
5-132 Gy,
8-105 Gy
12 mo 97% 81% 64% 3 years,
w50%
(ﬁgure 1)
1 year 83%,
2 years 68%,
(other survival
rates reported)
64 patients fatigue,
25 patients local
chest wall pain, 19
patients nausea, 12
patients dyspnea, 12
patients cough, 6
patients grade 3 or
higher pneumonitis
FEV1 54%
Baumann
(2009)122
57 40 T1,
17 T2
Peripheral 2.5 (range
0.6-5) cm
45 Gy/5/3,
15  3 at 67%
isodose line
Peripheral 113,
central 211
35 mo 3 years 92% 86% 65% 3 years
60%
1 year 93%, 2
years 88%, 3
years 88%
16 patients grade 3 Mean FEV1
64%
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Table 3 Continued
Author
(Year)
No.
Patients
Patients
per
Disease
Stage
Tumor
Location
Tumor
Size Dose BEDiso Follow-Up
Local
Control
Rate
1 Year
Survival
2 Year
Survival OS CSS
Complications
or Toxicities
Lung
Function
Criteria
Inoue
(2009)123
115 93 T1,
22 T2
Peripheral Median 2
(range
0.5-4.5) cm
30-70 Gy in
2-10 fractions
106 (range
56-141) Gy
14 mo 2 cm:
96.6%,
>2 cm:
94.7%
NA 3 years:
2 cm
89.8%,
>2 cm
60.7%
5 years:
2 cm 89.8%,
>2 cm 53.1%
NA; OS reported
based on 2
different size
groups
2 cm: 2 patients
grade 2; >2 cm: 5
patients grade 2
and 3 patients
grade 3; 1 patient
grade 5
ECOG 0-2
(WHO)
Guckenberger
(2009)124
124 (159
lesions)
118 Mets,
41 NSCLC
(13 stage IA,
19 stage IB,
9 T3N0)
Central, TW,
peripheral
NSCLC6, 9,
26; Mets,
16, 24, 78
CTV
29 cm3,
PM 8 cm3
12.5 Gy/3% to
65% isodose,
26 Gy/1% to
80% isodose,
10 Gy/3% to
65% isodose
84 Gy, 94 Gy,
60 Gy
Mean
18 mo,
median
14 mo
3 years 83% NA NA 3 years: 37%
NSCLC, 16%
Mets
3 years:
NSCLC 59%
Acute (24 patients),
19 patients, 1
patient grade 2, 3
pneumonitis,
2 patients II PT, 2
patients II PE, late
(6 patients), 3
patients II dyspnea,
2 patients II PT, 1
patient III
esophageal ulcer
Karnofsky
index 77, 89
Fakiris
(2009)125
70 34 T1,
36 T2
48 peripheral,
22 central
7 cm T1: 20 Gy/3;
T2: 22 Gy/3
T1: 180 Gy;
T2: 211 Gy
50.2 mo 3 years,
88.1%
NA NA 3 years
42.7%
3 years
81.7%
6 patients grade 3; 1
patient grade 4; 5
patients grade 5
FEV1 <40%,
DLCO <40%
Bradley
(2010)115
91 58 T1N0M0,
22 T2N0M0,
2 T3N0M0,
6 T1N0M1
83 peripheral,
8 central
Median 2
(range
1-5) cm
Peripheral
18 Gy/3;
central
9 Gy/5
18 Gy group:
151 Gy; 9 Gy
group: 85.5 Gy
18 mo 2 years, 86%,
3 years,
w86%
(ﬁgure 1)
NA NA 3 years
w60%, 4
years w50%
3 years w73%,
4 years w65%
(ﬁgure 4)
3 patients grade 2
pneumonitis;
4 patients rib fracture
or chest wall pain; 1
patient brachial
plexopathy
FEV1 46%,
DLCO 49%
Timmerman
(2010)116
55 44 T1,
11 T2
Peripheral <5 cm 18 Gy/3 151.2 Gy 34.4 mo 87.2% w87% w75% 3 years
55.8%
3 years
48.3%
7 patients grade 3; 2
patients grade 4
FEV1 <40%,
DLCO <40%
Haasbeek
(2010)127
193 (203
tumors)
118 T1,
85 T2
83 peripheral,
8 central
Median2
(range
1-5) cm
69-20 Gy/3,
101-112 Gy/5,
33-7.5 Gy/8
3-180 Gy,
5-132 Gy,
8-105 Gy
12.6 mo 3 years 89% 85.7% NA 3 years
45.1%;
median OS
32.5 mo
3 pneumonitis
2.1%, cough 5.7%,
chest wall pain 2.6%,
dyspnea 5.2%
Severe COPD
in 25%; 80%
inoperable;
20% declined
surgery
Abbreviations: BED ¼ biologic effective dose; COPD ¼ chronic obstructive pulmonary disease; CSS ¼ cause-speciﬁc survival; CTV ¼ clinical target volume; DLCO ¼ carbon monoxide diffusing capacity; ECOG ¼ Eastern Cooperative Oncology Group; FEV1 ¼ forced expiratory
volume in 1 second; LL ¼ lower lobe; Mets ¼ metastases; ML ¼ middle lobe; NA ¼ not applicable; NSCLC ¼ nonesmall cell lung cancer; OS ¼ overall survival; PE ¼ pulmonary embolism; PT ¼ pulmonary thrombosis; RT ¼ radiotherapy; UL ¼ upper lobe; WHO ¼ World
Health Organization.
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Guy C. Jones et alcomplications increased with doses greater than 25 Gy with
increased risk of pulmonary toxicity in patients with treatment
volumes greater than 50 cm3 and in those with a history of pul-
monary radiation.
Hof and colleagues109 reported on 42 patients with stage IA
(n ¼ 17), IB (n ¼ 21), or IIB (n ¼ 4) NSCLC. Patients were
treated with 15 to 30 Gy prescribed to the isocenter with the 80%
isodose covering the planning target volume. With a median follow-
up of 15 months, LC and OS rates at 1, 2, and 3 years were 89.5%,
67.9%, and 67.9%, and 74.5%, 65.4%, and 37.4%, respectively.
Koto and colleagues119 reported on 31 patients with a median tu-
mor size of 2.5 cm with a median follow-up of 32 months. Patients
were treated with either 60 Gy in 8 fractions (if the tumor was close
to an organ at risk) or 45 Gy in 3 fractions. The 3-year LC rate for
patients with stage IA disease (n ¼ 19) was 77.9%, compared to
40% for stage IB disease (n ¼ 12). The 3-year OS and CSS rates for
the entire cohort were 71.7% and 83.5%, respectively.
Onishi and colleagues120 reported on an amalgamation of multi-
institutional data from Japan that included 257 patients (164 pa-
tients with stage IA disease and 93 with stage IB disease) with a
median tumor size of 2.8 cm (range, 0.7 to 5.8 cm). Of the 257
patients, 99 had medically operable disease but refused surgery. The
median follow-up period for the entire cohort was 38 months.
Given the heterogeneity of radiotherapy dose prescriptions, the
cohort was dichotomized into 2 groups, with 215 patients
receiving  100 Gy BED and the other 42 patients receiving < 100
Gy BED. The overall LC rate for the entire cohort was 86% (87.8%
for stage IA and 82.8% for IB, which was deemed to be signiﬁcantly
different, P ¼ .21). The group that received  100 Gy BED had a
LC rate of 91.6%, while those who received a BED < 100 Gy had a
LC rate of only 57.1% (P < .001). The 3- and 5-year OS for the
entire cohort was 56.8% and 47.2%, respectively. The 5-year OS
for the BED 100 Gy cohort was 53.9%, compared to only 19.7%
for < 100 Gy (P < .05). With a median follow-up of 58 months,
the operable group treated with SBRT alone to a BED > 100 Gy
demonstrated 5-year OS and local PFS rates comparable to histor-
ical lobectomy controls.85
Lagerwaard and colleagues121 published the results of 206 pa-
tients with tumor sizes of  6 cm treated with a variety of frac-
tionation schemes based on tumor stage and risk of toxicity to
surrounding normal tissue (20 Gy  3, 12 Gy  5, and 7.5 Gy  8
fractions). With a median follow-up of 12 months, the LC was 97%
with median OS at 1 and 2 years of 81% and 64%, respectively.
The 1- and 2-year CSS were 83% and 68%. Severe late toxicity was
observed in less than 3% of patients. Baumann and colleagues122
reported on 57 patients with an average tumor size of 2.5 cm
(range, 0.6 to 2.5 cm). The median follow-up was 35 months with a
3-year LC was 92%. In terms of OS, the 1-, 2-, and 3-year rates
were 86%, 65%, and 60%, respectively. The CSS at these time
intervals was 93%, 88%, and 88%, respectively.
Inoue et al123 studied 115 patients with a median tumor size of 2
cm at a median follow-up of 14 months. Tumors  2 cm had a LC
of 96.6%, compared to 94.7% for larger tumors. OS rates for the
group with  2 cm tumors at 3 and 5 years were both 89.8%. The
OS of the group with tumors > 2 cm at 3 and 5 years were 60.7%
and 53.1%, respectively. Guckenberger and colleagues124 reported
on 124 patients in their study, which included 41 patients withNSCLC and the remainder with pulmonary metastases. Average
tumor size for those with NSCLC was 8 cm3. The median follow-
up time was 14 months, and 3-year LC was 83%. For the NSCLC
patients in the study (n ¼ 41), the 3-year OS and CSS were 37%
and 59%. This group also evaluated the impact of BED and found
that 3-year LC was 89% versus 62% in favor of BED > 100 Gy.
Fakiris and colleagues125 reported on 70 patients with tumors  7
cm. The average follow-up time was 50.2 months, and the LC at 3
years was 88.1%. The OS and CSS at 3 years were 42.7% and
81.7%, respectively.
A retrospective report from the Cleveland Clinic explored the
effect of 2 different fractionations on tumor control and toxicity.
Eighty-six consecutive patients (with 94 lesions) with medically
inoperable stage I NSCLC received either 50 Gy in 10 Gy fractions
or 60 Gy in 20 Gy fractions. The change in fractionation reﬂected
a change in institutional practice based on date of treatment
delivery rather than a clinical treatment selection. LC for the 50
and 60 Gy cohorts at 1 year were 97.3% and 100%, and OS was
83.1% and 76.9%, respectively, which were not signiﬁcantly
different. The only signiﬁcant difference between the cohorts was
the incidence of mild (grade 1 or 2) chest wall toxicity, which was
higher in the 60 Gy group (18% vs. 4%, P ¼ .028). Thus, the
authors concluded that tumor control was not affected by this
change in fractionation, but chest wall toxicity was increased with
60 Gy in 20 Gy fractions.126 Haasbeek et al127 retrospectively
reviewed the role of SBRT in patients  75 years of age with early
stage NSCLC (118 T1 tumors and 85 T2 tumors) deemed
medically inoperable or in those who refused surgery. Two hun-
dred three tumors were treated in 193 patients with utilization of 3
risk-adapted fractionation schemes based on the location of the
tumor (20 Gy  3, 12 Gy  5, and 7.5 Gy  8 fractions). OS at 1
and 3 years was 86% and 45%, respectively, with a median survival
of 32.5 months. The 3-year LC was 89%. The authors noted
minimal acute toxicity with uncommon severe late toxicity with
grade 3 or higher late toxicity in less than 10% of patients.
Bishawi and colleagues39 reviewed 30 patients with stage I and II
NSCLC treated with SBRT alone (60 Gy in 3 fractions). The main
focus of the review was to assess the effects of SBRT on FEV1 and
DLCO. FEV1 before and after treatment did not change dramati-
cally in patients with and without COPD (39  5 vs. 40  9,
P ¼ .4; 77  0.5 vs. 73  24, P ¼ .9). DLCO, on the other hand,
signiﬁcantly improved for those who did not have COPD but not
for patients with COPD (60  24 vs. 69  22, P ¼ .022; 49  13
vs. 50 , P ¼ .8).
Sher and colleagues40 compared costs of SBRT, 3-D conformal
radiotherapy, and RFA for treatment of medically inoperable stage I
NSCLC. In their study, a model was created to describe the health
status of a 65-year-old man with early stage NSCLC treated with 1
of the 3 modalities listed above. It was assumed that patients
received supportive care at recurrence. Data for cost and recurrence
were adapted from the literature and utility values were computed.
The incremental annual quality-adjusted life years’ value of SBRT
over RFA and 3-D chemoradiotherapy were US$14,000 and
US$6000, respectively.
From the literature, it can be concluded that LC and OS
for patients with NSCLC treated with SBRT are superior to con-
ventional radiotherapy and appear similar to surgical outcomes.Clinical Lung Cancer November 2015 - 427
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selection biases, and limited follow-up, it is important to complete
further prospective trials. Another important caveat is that SBRT is
commonly performed in medically inoperable patients in which
histologic conﬁrmation through biopsy is often avoided as a result of
the procedure’s risks. In the Haasbeek et al127 experience, for
instance, the rate of histologic conﬁrmation of malignancy was only
39%, which they report as being in line with other similar studies.
In the absence of pathology, institutions and national organizations
are developing consensus guidelines for establishing a diagnosis of
malignancy using radiographic criteria such as 18F-ﬂudeoxyglucose
uptake and documented growth. A recent publication by Louie
et al128 describes an inventive model for comparison between several
approaches in this situation.
To address several of the critical issues surrounding SBRT, the
RTOG conducted a number of recent trials. The RTOG 0915
study compared 2 SBRT fractionation schedules including 48 Gy in
4 fractions and 34 Gy in a single fraction. The study met its accrual
objective and was presented as an abstract at the 2013 ASTRO
annual meeting with 20.6 months of follow-up. At 1 year, the
single-fraction regimen met prespeciﬁed criteria with respect to
adverse events and tumor control; thus, this regimen has been
selected as the experimental arm for a planned phase 3 trial.
The RTOG 0618 trial studying the use of SBRT in patients with
operable, early stage disease closed to accrual in 2010, and the
RTOG 0813 trial studying the treatment of centrally located
tumors was closed in 2013. Both studies met their accrual objec-
tives, with data maturing at the present time. Unfortunately, the
RTOG 1021/ACOSOG Z4099 study comparing sublobar resec-
tion with or without brachytherapy to SBRT in high-risk operable
patients was closed in 2013 as a result of slow accrual, as were the
Dutch ROSEL and Accuray STARS trials, both comparing lobec-
tomy and SBRT.
Conclusion
In summary, patients with early stageNSCLCdeemed to be at high
risk or medically inoperable, or patients who otherwise refuse lobec-
tomy, have new options for treatment with evidence to support
promising results and manageable toxicities. Such techniques,
including RFA and SBRT, provide options for patients unable to
undergo lobectomy or even limited resection, and they allow for the
possibility of improved LC and OS compared to historical controls.
Further studies are required to better deﬁne the optimal treatment of
patients with early stageNSCLC to include a deﬁnitive comparison of
SBRT to surgical resection in patients with operable disease.
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